Biosimilars – Keys to Success in the Pharmacy Benefit
Generics + Biosimilars Conference
Alex Brill participated in a panel with Nick Adolph and Sarah D’Orsie for the GRx+Biosims conference. The market entry of biosimilar insulin and multiple versions of biosimilar Humira have signaled a new era in biosimilar competition. As primarily pharmacy-benefit products, the opportunities and challenges for adoption can vary from those facing provider-administered biosimilars. This panel will review the state of the market and any lessons from the launches to date.
Find more information on the conference here.